Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Further Consideration of the Pigmented Lesion Assay

Further Consideration of the Pigmented Lesion Assay Letters Toshiya Handa, MD about 1 in 11 melanomas tested would be missed, even if that Takafumi Kamiya, MD sensitivity is confirmed in subsequent evaluation. There- Yasuyuki Sumikawa, MD fore, we are concerned that if the PLA is widely used, the ac- Tomoyuki Minowa, MD tual number of missed melanomas may be substantial. We rec- Ayako Kumagai, MD ommend that prior to widespread use, the PLA be carefully Masahide Sawada, MD tested on diverse populations by independent groups. Hisashi Uhara, MD Meghan Beatson, BS Author Affiliations: Department of Dermatology, Sapporo Medical University, Martin A. Weinstock, MD, PhD Sapporo, Japan. Corresponding Author: Takafumi Kamiya, MD, Department of Dermatology, Author Affiliations: Department of Dermatology, Alpert Medical School of Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Brown University, Providence, Rhode Island (Beatson, Weinstock); Center for Sapporo 060-8543, Japan (kamitaka@sapmed.ac.jp). Dermatoepidemiology, Providence VA Medical Center, Providence, Rhode Island (Beatson, Weinstock); George Washington University School of Medicine, Published Online: January 30, 2019. doi:10.1001/jamadermatol.2018.5379 Washington, DC (Beatson). Conflict of Interest Disclosures: None reported. Corresponding Author: Meghan Beatson, BS, Center for Additional Contributions: We thank the patient for granting permission to Dermatoepidemiology, Providence VA Medical Center, 830 Chalkstone Ave, publish this information. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Further Consideration of the Pigmented Lesion Assay

JAMA Dermatology , Volume 155 (3) – Mar 30, 2019

Loading next page...
 
/lp/american-medical-association/further-consideration-of-the-pigmented-lesion-assay-DRIAViV142

References (2)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2018.5478
Publisher site
See Article on Publisher Site

Abstract

Letters Toshiya Handa, MD about 1 in 11 melanomas tested would be missed, even if that Takafumi Kamiya, MD sensitivity is confirmed in subsequent evaluation. There- Yasuyuki Sumikawa, MD fore, we are concerned that if the PLA is widely used, the ac- Tomoyuki Minowa, MD tual number of missed melanomas may be substantial. We rec- Ayako Kumagai, MD ommend that prior to widespread use, the PLA be carefully Masahide Sawada, MD tested on diverse populations by independent groups. Hisashi Uhara, MD Meghan Beatson, BS Author Affiliations: Department of Dermatology, Sapporo Medical University, Martin A. Weinstock, MD, PhD Sapporo, Japan. Corresponding Author: Takafumi Kamiya, MD, Department of Dermatology, Author Affiliations: Department of Dermatology, Alpert Medical School of Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Brown University, Providence, Rhode Island (Beatson, Weinstock); Center for Sapporo 060-8543, Japan (kamitaka@sapmed.ac.jp). Dermatoepidemiology, Providence VA Medical Center, Providence, Rhode Island (Beatson, Weinstock); George Washington University School of Medicine, Published Online: January 30, 2019. doi:10.1001/jamadermatol.2018.5379 Washington, DC (Beatson). Conflict of Interest Disclosures: None reported. Corresponding Author: Meghan Beatson, BS, Center for Additional Contributions: We thank the patient for granting permission to Dermatoepidemiology, Providence VA Medical Center, 830 Chalkstone Ave, publish this information.

Journal

JAMA DermatologyAmerican Medical Association

Published: Mar 30, 2019

There are no references for this article.